Related Experiment Videos
Multiple risk factor evaluation in a hypertension clinic
S Thom1, J Bunker, W Callister
1Hypertension Clinic, St Mary's Hospital, London, UK.
Insights
Hypertension management can improve cardiovascular health. Adjusting antihypertensive drugs and diet significantly reduced cholesterol, triglycerides, and weight in patients, lowering coronary heart disease risk.
Area of Science:
- Cardiology
- Metabolic Disorders
Background:
- Hypertension is linked to abnormal lipoprotein metabolism.
- Certain antihypertensive drugs may worsen lipid profiles.
- This dyslipidemia is a significant coronary heart disease risk factor.
Purpose of the Study:
- To assess the impact of dietary advice and antihypertensive therapy adjustments on lipid metabolism in hypertensive patients.
- To quantify the reduction in cardiovascular risk factors.
Main Methods:
- A cohort of 65 hypertension patients were reassessed over 3-21 months.
- Interventions included dietary advice and modification of antihypertensive therapy.
- Measurements included total cholesterol, serum triglycerides, and body weight.
Main Results:
- 75% of patients had elevated fasting serum cholesterol (>5.2 mmol/l).
- Significant reductions observed: total cholesterol (14%), serum triglycerides (18%), and body weight (4.3%).
Conclusions:
- Dietary changes and adjusted antihypertensive therapy effectively improve lipid profiles and reduce weight in hypertensive individuals.
- These improvements translate to a substantial estimated reduction (at least 28%) in major coronary heart disease event risk.
Abstract:
Hypertension is associated with abnormal lipoprotein metabolism, which may be exacerbated by some groups of antihypertensive drugs and represents an additional powerful coronary heart disease risk factor. Of our Hypertension Clinic population, 75% had a total fasting serum cholesterol greater than 5.2 mmol/l. Dietary advice and adjustment of antihypertensive therapy has achieved significant reductions in total cholesterol, serum triglycerides and body weight (14%, 18% and 4.3%, respectively) in a cohort of 65 patients reassessed over a period of 3-21 months. The reduction in cholesterol is likely to represent at least a 28% reduction in the risk of a major coronary heart disease event, even before taking account of any improvement in other coronary heart disease risk factors.